• Sponsored Content

BPI Staff

July 18, 2019

1 Min Read

2019-BIO-Theater-Avid-300x156.pngRay Marzouk, vice president of quality at Avid Bioservices, joined the BPI Theater at BIO on Wednesday, 5 June 2019, to call out factors that drug developers often neglect when they are deciding whether to enlist a contract development manufacturing organization (CDMO) for scaling up and introducing new therapies in a competitive market. Citing examples related to ICH Q5d cell banking rules, Marzouk explained how Avid conducts smooth and rapid transfers of key process elements and quality diagnostics. Streamlining that transfer, Marzouk concluded, improves process reliability and efficiency as a product makes its way through development and transfer. Equally important, it results in improved product quality.

You May Also Like